J3389 HCPCS Reimbursement & Policy Benchmarks

HCPCS Level II code J3389 designates topical administration of prademagene zamikeracel, billed per treatment. As a drug-administration code, it captures a specific topical therapy encounter and matters nationally because it affects drug billing workflows, payer coverage evaluations, and clinical documentation practices for outpatient topical oncology or specialty dermatologic applications. Analysis typically examines coverage policies, allowed amounts, utilization patterns, and coding guidance relevant to hospital outpatient departments and physician offices.

Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, typical sites of service, and where to look for benchmarks and policy updates. The publication outlines clinical context for topical administration, billing and documentation elements linked to per-treatment drug delivery, and identifies gaps where payer-specific policy details or utilization data are not provided. Data not available in the input will be noted where applicable.

Billing Code Overview

HCPCS Level II code J3389 describes topical administration of prademagene zamikeracel, per treatment. This code represents a drug delivery service in which the specified agent is applied topically to a patient as an individual treatment session. The service type is topical drug administration. The typical site of service is outpatient clinic or physician office settings where topical therapeutic agents are administered under clinical supervision.

Data not available in the input.

Clinical Context

A typical patient is an adult with a surface-accessible cutaneous or mucosal neoplasm enrolled in a clinical protocol or receiving an FDA-authorized topical gene-modulating therapy using prademagene zamikeracel. The patient presents to a dermatology, oncology, or surgical oncology clinic or an ambulatory infusion/oncology treatment center for topical application. Pre-treatment evaluation includes confirmation of diagnosis, review of prior therapies, informed consent, and documentation of lesion location, size, and number. On the day of service the patient is positioned, the treatment area is cleansed and prepared per product instructions, and J3389 is administered as a topical application to the targeted lesion(s) by a qualified clinician or trained nurse. Post-application observation is performed for local reactions; procedure details and lot numbers are documented in the medical record. Follow-up visits assess local response, adverse events, and need for repeat topical treatments per protocol or prescribing information.

Coding Specifications

Modifier	Description	When to Use
`25`	Significant, Separately Identifiable Evaluation and Management Service by the Same Physician on the Day of a Procedure	Use when a separately identifiable E/M visit is provided on the same day as `J3389` and documented accordingly.

Taxonomy Code	Specialty	Notes
`208000000X`	Dermatology	Primary specialty for topical cutaneous therapeutic application and lesion assessment.
`207RG0100X`	Medical Oncology	Management of cancer therapies and coordination of topical investigational oncologic agents.
`2086S0102X`	Dermatopathology	Diagnostic evaluation and pathology correlation for cutaneous neoplasms treated topically.
`207L00000X`	Surgical Oncology	Surgical assessment and combined procedural planning when topical therapy is adjunctive.
`364S00000X`	Ambulatory Infusion/Injection Services	Clinic or center providers administering topical or investigational topical agents and monitoring patients.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C44.9`	Malignant neoplasm of skin, unspecified	Common code for cutaneous malignancies when specific site is not documented and topical oncologic therapy is considered.
`C44.3`	Malignant neoplasm of skin of other and unspecified parts of face	Relevant when topical prademagene zamikeracel is applied to facial skin cancers.
`C44.2`	Malignant neoplasm of skin of scalp and neck	Relevant for topical treatment of lesions in the scalp/neck region.
`D04.9`	Carcinoma in situ of skin, unspecified	Used when treating in situ keratinocytic neoplasms amenable to topical therapy.
`L57.0`	Actinic keratosis	Premalignant lesion often treated with topical therapies; may be relevant in differential management and topical protocols.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Often used for the pre-treatment evaluation or follow-up visit when a separate E/M is documented on the day of topical application of `J3389`.
`96423`	Chemotherapy administration into the skin by topical, percutaneous or mucosal route; single or initial substance/drug	Used for billing topical or mucosal administration techniques when payers require a procedure code for topical drug administration (note: confirm payer acceptance with `J3389`).
`11100`	Biopsy of single skin lesion; tangential, shave, or punch	Performed before topical therapy for diagnostic confirmation of a lesion targeted for `J3389` application.
`11719`	Trimming of dystrophic nails, any number; each additional toe or finger (list separately in case of nail matrix-involved topical therapy)	May be performed when lesion preparation involves nail dystrophy prior to topical application.
`99070`	Supplies and materials (except spectacles) provided by the physician over and above those usually included with the office visit or procedure	Used to report special supplies or disposables associated with topical application of an investigational product when payers permit ancillary supply billing.

OpenPayer

Summary & Overview

HCPCS J3389: Topical Prademagene Zamikeracel, Per Treatment